The intra-nasal booster vaccine against SARS-CoV-2 has been developed using codon deoptimisation technology

Indian Immunologicals Limited (IIL) has announced a live-attenuated needle-free intra-nasal booster vaccine developed against SARS-CoV-2 using codon deoptimisation technology in collaboration with Griffith University, Australia. The groundbreaking work on the COVID-19 vaccine was published in the world’s leading science journal Nature Communications on August 26, 2024.

IIL’s needle-free intra-nasal booster vaccine against SARS-CoV-2 developed using codon deoptimisation technology demonstrated remarkable stability and maintained safety in extensive animal studies.

Dr K Anand Kumar, MD, IIL said, “This accomplishment signifies a major step forward in our battle against COVID-19. The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates IIL’s capability to adopt novel technology. We are enthusiastic about the codon de-optimisation technology, and it’s use in targeted attenuation of microorganisms to be used as vaccine candidates”.

Dr Priyabrata Pattnaik, Deputy MD, IIL added “This is a perfect example of Industry-Academia collaboration translating concepts to products for the benefit of people at large. Our R&D team has dedicated immense effort to creating this innovative vaccine, and we take pride in its proven safety and efficacy in generating a protective immune response with just a single dose."